Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Non-viral gene delivery systems for osteoarthritis therapy

Zhang C., Zhao H., Zhang Z., Gao Y., Gao R., Wang J.

Narrative Review on Osteoarthritis, published in Biomater Transl (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biomater Transl (2026)
Reported sample size
—
Source database
Europe PMC
PMID
42179767
PMCID
PMC13190108
DOI
10.12336/bmt.24.00084

Abstract (original English)

Osteoarthritis (OA) is a degenerative joint disease marked by periarticular bony overgrowth and the degradation of articular cartilage, leading to severe pain, impaired joint function, and reduced quality of life for those affected. Current OA treatments, including pharmacotherapy, physical therapy, and joint replacement surgery, often provide limited therapeutic benefits and are associated with various side effects. As a result, there is a pressing need for alternative treatment options. Gene therapy has emerged as a promising approach for achieving longer-lasting benefits by repairing or modulating the molecular and cellular mechanisms within the joint. Specifically, gene therapy for OA involves either suppressing the expression of detrimental genes or enhancing the expression of therapeutic genes. The success of these approaches, however, significantly depends on the safe and efficient delivery platforms used. Given the risks of insertional mutations and high production costs associated with viral vectors, considerable efforts have been made to develop non-viral systems as safer and more cost-effective alternatives for gene delivery. Over the past few decades, a variety of innovative non-viral vectors with integrated functions have been proposed, successfully overcoming the challenges of gene delivery. The substantial progress made in the rational design of these vectors, al

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research